Kintara Therapeutics Inc KTRA shares are trading higher Monday after the company was granted FDA fast track designation for REM-001 for the treatment of patients with cutaneous metastatic breast cancer.
REM-001 was studied in four Phase 2/3 clinical trials in patients with cutaneous metastatic breast cancer who had previously received chemotherapy or failed radiation therapy. Clinical efficacy to-date is approximately 80% when measured as complete responses of cutaneous metastatic breast cancer evaluable lesions.
"We believe this designation is a key component of our future clinical and regulatory strategy as we continue to seek funding, in particular grants, to restart REM-001 clinical development as soon as possible," said Robert Hoffman, president and CEO of Kintara.
Kintara Therapeutics is a biopharmaceutical company focused on the development of new solid tumor cancer therapies.
See Also: US Stocks Head For Rough Start To Week As China Protests Become International Concern
KTRA Price Action: Kintara has a 52-week high of $42 and a 52-week low of $3.50.
The stock was up 25.8% at $4.64 at time of publication, according to Benzinga Pro.
Photo: Michal Jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
